Polarean Imaging successfully enrol 80 patients for its clinical trials
Francesca Morgan
Company News - 2 mins
08:48, 7th November 2019

Medical imaging technology company, Polarean Imaging (POLX) FOLLOW, announced on Thursday the successful completion of patient enrollment for its phase III clinical trials.

The clinical trials, with its aim to demonstrate non-inferiority of the group’s drug-device combination, enrolled a total of 80 patients — out of these, 48 were designated to lung transplant whilst 32 were in lung resection.

The following readout process will now move to image and statistical analysis, the company explained -- this is a process to conclude the readout which is expected to take around 10 weeks.

The completion of the readout is important to form the basis for an NDA, or a Pre-New Drug Application meeting with the FDA, as emphasised by regulatory consultants of the group.

Following a pre-NDA meeting, with its considerations incorporated into a submission, the process will conclude with Polarean’s submission which the company expects to be made by the end of Q2 2020.

"The Company is pleased to have successfully completed enrolment for its Clinical Trials and looks forward to the next stage of statistical analysis ahead of readout and the proposed submission of the NDA,” said Richard Hullihen, Polarean’s Chief Executive.

Additionally, Polarean further announced the appointment of Mr. Alex Dusek as Vice-President of Commercialisation as the group ramps up preparation for commercialisation.

Having led product launches at multinational biotechnology firms like Bayer and United Therapeutics, Mr Dusek will bring with him “a wealth of direct pharmaceutical industry launch preparation" that is consistent with Polarean’s commercial targets. 

Follow News & Updates from Polarean Imaging here: FOLLOW

Disclaimer & Declaration of Interest

The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.

Login or register to post comments

Recent Articles